Q & A Highlights
Q: Can you provide details on the newly announced strategic manufacturing and supply agreement, including the nature of the partner, the product mix, and the expected revenue ramp-up timeline?A: Ravi Mitra (CFO) and Srinivas Sadu (Executive Chairman) explained that this is with a leading global specialty pharma company, covering a mix of generics (60-70%) and complex/specialty products (30-40%). The agreement covers 55 SKUs of oncology and non-oncology injectables manufactured across three Indian sites, with Cenexi providing European warehousing and QP release. Technology transfer begins in September 2026, with revenues expected to commence in calendar year 2029 and ramp up to the full potential of USD90-100 million by calendar year 2030. The deal provides strong long-term visibility and is expected to contribute to a revised growth outlook of approximately 20% CAGR over the next four years.
Q: What is the current status of the GLP-1 business, and what is the expected revenue contribution over the next three years?A: Srinivas Sadu (Executive Chairman) stated that the new capacity line is on track, and the company is currently producing exhibit batches for customers. A new contract was signed this quarter for both semaglutide and tirzepatide for the US and EU markets. However, revenue contribution is expected to be very limited over the next three years, as major volumes are anticipated from FY30-31. The company has not factored significant GLP-1 revenue into its guidance, though a potential launch in Canada by a customer could provide an upside in the last quarter of the current fiscal year.
Q: How sustainable is the turnaround at Cenexi, and what is the updated guidance for FY27?A: Srinivas Sadu (Executive Chairman) confirmed that Cenexi’s performance is improving, with Q1 FY27 revenue of EUR48 million and EBITDA of EUR2 million (4% margin). Despite the summer heat wave impacting quality releases, the Fontenay facility benefited from the new ampoule line ramp-up. The company maintains its FY27 guidance of approximately EUR200 million revenue and high single-digit EBITDA margins. Q2 is expected to be better than last year as some shipments delayed from Q1 will be released.
Q: What is the revenue potential and timeline for the new strategic collaborations with Neuland Laboratories and the China-based liposomal product partner?A: Srinivas Sadu (Executive Chairman) explained that the Neuland collaboration is a strategic extension of an existing supply agreement for sterile APIs for microparticle depot products. A new suite is being built to address capacity constraints, as the current capacity is fully occupied with only 2 APIs, while 5-6 more products are in the pipeline. The liposomal in-licensing agreement covers a niche product for the US and EU markets, with a global market estimated at $1.6 billion currently and $3 billion in three years. Commercial opportunities are expected to start from FY30, with the company investing in a dedicated compounding suite and targeting the patent expiry date.
Q: How should we think about the CDMO vs. B2B business mix and the margin profile going forward?A: Srinivas Sadu (Executive Chairman) stated that the company aims to maintain a balanced mix of around 50-50 between CDMO and B2B for the next two years, with CDMO potentially becoming larger by CY ’29. On margins, the near-term target is 30% consolidated EBITDA, with a longer-term aspiration of 35% EBITDA in the next three to four years as CDMO contracts scale up. The company believes CDMO margins can be superior due to the leverage from manufacturing products that were previously produced in more expensive locations.
Q: What is the constant currency growth for the quarter, and how should we interpret the reported 20% YoY growth?A: Ravi Mitra (CFO) clarified that the constant currency growth for Q1 FY27 was 15%, with the difference from the reported 20% growth attributable to favorable foreign exchange movements. Srinivas Sadu (Executive Chairman) added that the company’s guidance is based on constant currency, and the 15% growth target for FY27 is achievable, with potential upside if the bag line receives FDA approval in Q3 and if a GLP-1 customer launches in Canada.
Q: Can you provide an update on the base business growth in the US and other markets, excluding the impact of new launches and foreign exchange?A: Srinivas Sadu (Executive Chairman) indicated that the base business grew by 24% year-on-year. The US market grew by 32%, and after adjusting for a ForEx gain of around 5%, the constant currency growth for the base business was approximately 19-20%. This growth was driven by volume expansion from existing customers and improved competitiveness from cost optimization initiatives.
Q: What is the current status of the Dr. Reddy’s partnership on biologics, and are there any updates on new partnerships?A: Srinivas Sadu (Executive Chairman) stated that the Dr. Reddy’s partnership is generating normal business of around INR50-60 crores annually, with a slow ramp-up expected over the next year or two. No significant new contracts have been signed recently in the biologics space, and the company’s current CDMO discussions are primarily focused on the peptide side.
Q: What is the profit share percentage for the quarter, and what are the timelines for the NDDS project?A: Srinivas Sadu (Executive Chairman) confirmed that the profit share for Q1 FY27 was approximately 9%. Regarding the NDDS (Nano Drug Delivery System) project, the timeline is for development completion in FY28 and commercialization in FY29, with a revenue potential of $25-30 million.
Q: How should we think about the growth of the US business given the current run rate of over $100 million and the pipeline of complex products?A: Srinivas Sadu (Executive Chairman) noted that while the overall US injectable market is growing at only 3-4%, Gland Pharma’s growth in the US is consistently higher due to new product launches and the ability to gain market share from competitors through a better cost structure. The company’s complex product pipeline, including microsphere products, is expected to be a significant growth driver post-FY29, with several large opportunities currently in clinical or exhibit stages.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
